RBPWorld - a comprehensive database of RNA Binding Proteins

Drugs target to PARP3

Drug name	Drug type	Disease/phenotype	Mechanism of action(MoA)	Phase	Status	Source
OLAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Terminated	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	endometrial cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	cholangiocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	cancer	PARP 1, 2 and 3 inhibitor	1.0	Unknown status	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	4.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	primary peritoneal carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	Hereditary breast and ovarian cancer syndrome	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	pancreatic carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Unknown status	ClinicalTrials
VELIPARIB	Small molecule	triple-negative breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	metastatic malignant neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	Mantle cell lymphoma	PARP 1, 2 and 3 inhibitor	1.0	Unknown status	ClinicalTrials
RUCAPARIB	Small molecule	peritoneum cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	lung cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	head and neck squamous cell carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Withdrawn	ClinicalTrials
OLAPARIB	Small molecule	pancreatic carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate adenocarcinoma	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	pancreatic carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Unknown status	ClinicalTrials
VELIPARIB	Small molecule	undifferentiated carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	angiosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	pancreatic ductal adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	metastatic melanoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	3.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	metastatic colorectal cancer	PARP 1, 2 and 3 inhibitor	2.0	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	metastatic prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	soft tissue sarcoma	PARP 1, 2 and 3 inhibitor	3.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	gastric cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	2.0	Withdrawn	ClinicalTrials
VELIPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	glioblastoma multiforme	PARP 1, 2 and 3 inhibitor	0.5	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	chronic lymphocytic leukemia	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	urinary bladder carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	3.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	cutaneous melanoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	0.5	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	prostate adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	mesothelioma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	glioblastoma multiforme	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	soft tissue sarcoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	Ovarian Transitional Cell Carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	urinary bladder cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	3.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	Primary Peritoneal Serous Adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	prostate adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	metastatic melanoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	metastatic malignant neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	disease of genitourinary system	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	pancreatic adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	squamous cell carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Withdrawn	ClinicalTrials
RUCAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	bile duct cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	breast carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Suspended	ClinicalTrials
OLAPARIB	Small molecule	Uveal Melanoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	gastric cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	Hereditary breast and ovarian cancer syndrome	PARP 1, 2 and 3 inhibitor	2.0	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	soft tissue sarcoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	Hereditary breast and ovarian cancer syndrome	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	cervical carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	3.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	acinar cell carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	Hereditary breast and ovarian cancer syndrome	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	mesothelioma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	renal cell carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	0.5	Completed	ClinicalTrials
E-7016	Small molecule	melanoma	PARP 1, 2 and 3 inhibitor	2.0	Terminated	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	4.0	-	DailyMed
OLAPARIB	Small molecule	prostate adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	serous adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	neuroendocrine neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Terminated	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	gastric adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	uterine cancer	PARP 1, 2 and 3 inhibitor	1.0	Unknown status	ClinicalTrials
RUCAPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	head and neck squamous cell carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	metastatic melanoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	rectum cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	colorectal carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	germ cell tumor	PARP 1, 2 and 3 inhibitor	2.0	Unknown status	ClinicalTrials
OLAPARIB	Small molecule	breast carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	skin cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Terminated	ClinicalTrials
OLAPARIB	Small molecule	breast carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	1.0	Terminated	ClinicalTrials
RUCAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Terminated	ClinicalTrials
OLAPARIB	Small molecule	uterine leiomyosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	3.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	prostate adenocarcinoma	PARP 1, 2 and 3 inhibitor	3.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	pancreatic carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	Ovarian Carcinosarcoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	carcinoma	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	pancreatic ductal adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	ovarian serous adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	endometrial neoplasm	PARP 1, 2 and 3 inhibitor	3.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	sarcoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	cervical cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	1.0	Unknown status	ClinicalTrials
VELIPARIB	Small molecule	hepatocellular carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Terminated	ClinicalTrials
RUCAPARIB	Small molecule	peritoneum cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	high grade ovarian serous adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	peritoneum cancer	PARP 1, 2 and 3 inhibitor	2.0	Withdrawn	ClinicalTrials
OLAPARIB	Small molecule	malignant epithelial tumor of ovary	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	Hereditary breast and ovarian cancer syndrome	PARP 1, 2 and 3 inhibitor	2.0	Withdrawn	ClinicalTrials
RUCAPARIB	Small molecule	Uterine Carcinosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	glioma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	hepatocellular carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	carcinosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Unknown status	ClinicalTrials
RUCAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	glioblastoma multiforme	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	pulmonary arterial hypertension	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	Fallopian Tube Carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Withdrawn	ClinicalTrials
OLAPARIB	Small molecule	pancreatic adenocarcinoma	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	rhabdomyosarcoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	Fallopian Tube Carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	cervical cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	endometrial cancer	PARP 1, 2 and 3 inhibitor	0.5	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	bladder tumor	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	primary peritoneal carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Terminated	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	3.0	Enrolling by invitation	ClinicalTrials
OLAPARIB	Small molecule	pancreatic carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	prostate adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Terminated	ClinicalTrials
VELIPARIB	Small molecule	gliosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Unknown status	ClinicalTrials
VELIPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	testicular carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	squamous cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	Central Nervous System Neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	Malignant Ovarian Brenner Tumor	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	osteosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	peritoneum cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	endometrial cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	ovarian carcinoma	PARP 1, 2 and 3 inhibitor	4.0	-	FDA
OLAPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	4.0	-	DailyMed
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	2.0	Withdrawn	ClinicalTrials
OLAPARIB	Small molecule	peritoneal neoplasm	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	pancreatic carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	leiomyosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	colorectal carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	biliary tract cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	pulmonary arterial hypertension	PARP 1, 2 and 3 inhibitor	0.5	Terminated	ClinicalTrials
VELIPARIB	Small molecule	angiosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	metastatic colorectal cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	colorectal carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	malignant glioma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	3.0	Enrolling by invitation	ClinicalTrials
VELIPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	3.0	Withdrawn	ClinicalTrials
VELIPARIB	Small molecule	endometrioid carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	ovarian neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	Endometrial Serous Adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	colorectal carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	glioblastoma multiforme	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	gastric cancer	PARP 1, 2 and 3 inhibitor	1.0	Not yet recruiting	ClinicalTrials
VELIPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	4.0	-	ATC
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	2.0	Enrolling by invitation	ClinicalTrials
OLAPARIB	Small molecule	ovarian carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	peritoneal neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	1.0	Terminated	ClinicalTrials
RUCAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	endometrial carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	head and neck squamous cell carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	breast neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	mesothelioma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	triple-negative breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	endometrial cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
E-7016	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	prostate carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Terminated	ClinicalTrials
VELIPARIB	Small molecule	Central Nervous System Neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	breast carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	cervical cancer	PARP 1, 2 and 3 inhibitor	2.0	Withdrawn	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Unknown status	ClinicalTrials
VELIPARIB	Small molecule	breast carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	gastric cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	fallopian tube cancer	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Unknown status	ClinicalTrials
VELIPARIB	Small molecule	ovarian mucinous adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	endometrial cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	T-cell non-Hodgkin lymphoma	PARP 1, 2 and 3 inhibitor	1.0	Unknown status	ClinicalTrials
RUCAPARIB CAMSYLATE	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	non-Hodgkins lymphoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	Ewing sarcoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	3.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	Fallopian Tube Carcinosarcoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	primary peritoneal carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	peritoneum cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	anaplastic astrocytoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	male breast carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	cancer	PARP 1, 2 and 3 inhibitor	4.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB CAMSYLATE	Small molecule	prostate adenocarcinoma	PARP 1, 2 and 3 inhibitor	3.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	pancreatic adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	3.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	endometrium adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	3.0	-	ATC
OLAPARIB	Small molecule	inflammatory breast carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Unknown status	ClinicalTrials
OLAPARIB	Small molecule	pancreatic neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	metastatic colorectal cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	4.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	head and neck malignant neoplasia	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	cervical cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	renal cell carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	rectum cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	0.5	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	non-small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	Hereditary breast and ovarian cancer syndrome	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	lymphoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	head and neck squamous cell carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	3.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	primary peritoneal carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	gastric cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	primary peritoneal carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	pancreatic ductal adenocarcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	4.0	-	ATC
OLAPARIB	Small molecule	urinary bladder cancer	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	lymphoma	PARP 1, 2 and 3 inhibitor	1.0	Withdrawn	ClinicalTrials
OLAPARIB	Small molecule	metastatic prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	pancreatic carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	3.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	primary peritoneal carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	breast cancer	PARP 1, 2 and 3 inhibitor	1.0	Suspended	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	pancreatic ductal adenocarcinoma	PARP 1, 2 and 3 inhibitor	0.5	Recruiting	ClinicalTrials
RUCAPARIB	Small molecule	biliary tract cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	Ewing sarcoma	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	glioblastoma multiforme	PARP 1, 2 and 3 inhibitor	0.5	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	metastatic melanoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
VELIPARIB	Small molecule	ovarian clear cell adenocarcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
RUCAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	breast neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	small cell lung carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Terminated	ClinicalTrials
OLAPARIB	Small molecule	ovarian carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian carcinoma	PARP 1, 2 and 3 inhibitor	4.0	-	DailyMed
RUCAPARIB CAMSYLATE	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	4.0	-	DailyMed
RUCAPARIB	Small molecule	Hereditary breast and ovarian cancer syndrome	PARP 1, 2 and 3 inhibitor	2.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	carcinoma	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
VELIPARIB	Small molecule	cancer	PARP 1, 2 and 3 inhibitor	2.0	Withdrawn	ClinicalTrials
OLAPARIB	Small molecule	ovarian cancer	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
RUCAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
OLAPARIB	Small molecule	prostate cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
RUCAPARIB CAMSYLATE	Small molecule	ovarian carcinoma	PARP 1, 2 and 3 inhibitor	4.0	-	FDA
OLAPARIB	Small molecule	pancreatic carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	breast neoplasm	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials
OLAPARIB	Small molecule	metastasis	PARP 1, 2 and 3 inhibitor	1.0	Completed	ClinicalTrials
OLAPARIB	Small molecule	uterine leiomyosarcoma	PARP 1, 2 and 3 inhibitor	2.0	Not yet recruiting	ClinicalTrials
OLAPARIB	Small molecule	ovarian neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	ovarian carcinoma	PARP 1, 2 and 3 inhibitor	1.0	Withdrawn	ClinicalTrials
OLAPARIB	Small molecule	neoplasm	PARP 1, 2 and 3 inhibitor	1.0	Active, not recruiting	ClinicalTrials
VELIPARIB	Small molecule	triple-negative breast cancer	PARP 1, 2 and 3 inhibitor	2.0	Recruiting	ClinicalTrials

Welcome to

RBP World!

Drugs target to PARP3

Targets details